These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29125504)

  • 41. Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.
    Zhang S; Qin D; Wu L; Li M; Song L; Wei C; Lu C; Zhang X; Hong S; Ma M; Wu S;
    Orphanet J Rare Dis; 2021 Apr; 16(1):188. PubMed ID: 33910603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
    Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD
    J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
    King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
    Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation.
    Mori-Yoshimura M; Mitsuhashi S; Nakamura H; Komaki H; Goto K; Yonemoto N; Takeuchi F; Hayashi YK; Murata M; Takahashi Y; Nishino I; Takeda S; Kimura E
    J Neuromuscul Dis; 2018; 5(2):193-203. PubMed ID: 29614690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iranian Registry of Duchenne and Becker Muscular Dystrophies: Characterization and Preliminary Data.
    Bayat F; Sarmiento IG; Ahmadian N; Dehghani Z
    J Neuromuscul Dis; 2021; 8(2):251-259. PubMed ID: 33325392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy.
    Fang Y; McDonald CM; Clemens PR; Gordish HD; Illei K; Hoffman EP; ; Dang UJ
    J Neuromuscul Dis; 2023; 10(3):349-364. PubMed ID: 36806514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical practice with steroid therapy for Duchenne muscular dystrophy: An expert survey in Asia and Oceania.
    Takeuchi F; Nakamura H; Yonemoto N; Komaki H; Rosales RL; Kornberg AJ; Bretag AH; Dejthevaporn C; Goh KJ; Jong YJ; Kim DS; Khadilkar SV; Shen D; Wong KT; Chai J; Chan SH; Khan S; Ohnmar O; Nishino I; Takeda S; Nonaka I
    Brain Dev; 2020 Mar; 42(3):277-288. PubMed ID: 31980267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal natural history in young boys with Duchenne muscular dystrophy.
    Coratti G; Brogna C; Norcia G; Ricotti V; Abbott L; D'Amico A; Berardinelli A; Vita GL; Lucibello S; Messina S; Sansone V; Albamonte E; Colia G; Salmin F; Gardani A; Manzur A; Main M; Baranello G; Arnoldi MT; Parsons J; Carry T; Connolly AM; Bertini E; Muntoni F; Pane M; Mercuri E
    Neuromuscul Disord; 2019 Nov; 29(11):857-862. PubMed ID: 31629611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy.
    de Feraudy Y; Ben Yaou R; Wahbi K; Stalens C; Stantzou A; Laugel V; Desguerre I; ; Servais L; Leturcq F; Amthor H
    Ann Neurol; 2021 Feb; 89(2):280-292. PubMed ID: 33159473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care.
    Hong D; Avorn J; Wyss R; Kesselheim AS
    JAMA Netw Open; 2024 Jan; 7(1):e2353094. PubMed ID: 38265797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular characterization of exonic rearrangements and frame shifts in the dystrophin gene in Duchenne muscular dystrophy patients in a Saudi community.
    Elhawary NA; Jiffri EH; Jambi S; Mufti AH; Dannoun A; Kordi H; Khogeer A; Jiffri OH; Elhawary AN; Tayeb MT
    Hum Genomics; 2018 Apr; 12(1):18. PubMed ID: 29631625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan.
    Chien YH; Lee NC; Weng WC; Chen LC; Huang YH; Wu CS; Hwu WL
    Neurol Sci; 2022 Jul; 43(7):4563-4566. PubMed ID: 35562557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment.
    Merlini L; Cecconi I; Parmeggiani A; Cordelli DM; Dormi A
    Acta Myol; 2020 Dec; 39(4):200-206. PubMed ID: 33458575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determinants of usage and nonadherence to noninvasive ventilation in children and adults with Duchenne muscular dystrophy.
    Hurvitz MS; Bhattacharjee R; Lesser DJ; Skalsky AJ; Orr JE
    J Clin Sleep Med; 2021 Oct; 17(10):1973-1980. PubMed ID: 33949945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of steroid treatment on weight in nonambulatory males with Duchenne muscular dystrophy.
    Lamb MM; Cai B; Royer J; Pandya S; Soim A; Valdez R; DiGuiseppi C; James K; Whitehead N; Peay H; Venkatesh SY; Matthews D;
    Am J Med Genet A; 2018 Nov; 176(11):2350-2358. PubMed ID: 30256515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative study of care practices for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosis.
    Takeuchi F; Komaki H; Yamagata Z; Maruo K; Rodger S; Kirschner J; Kubota T; Kimura E; Takeda S; Gramsch K; Vry J; Bushby K; Lochmüller H; Wada K; Nakamura H
    Neuromuscul Disord; 2017 Oct; 27(10):894-904. PubMed ID: 28807665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.